VANCOUVER, BC, March 16, 2021 /PRNewswire/ - Delic Holdings. ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF), a psychedelic wellness-focused company, is pleased to announce the appointment of John Coleman, PhD, former President of Anandia Labs, as Vice President of Business Development.
Matt Stang commented "We are very fortunate to have John join our team. His pedigree between his corporate and scientific expertise is second to none. Having John join as our VP of Business Development shows our commitment to bringing top tier professionals to our team and having leaders in each pillar of our growing business."
John has a wide-ranging scientific and business background. In 2013, he co-founded Anandia Labs, a cannabis biotech company focused on genetics and analytics, and helped grow it to approximately 90 staff before Anandia was purchased in 2018 by Aurora Cannabis.
Prior to Anandia, John was the Department Head of the Centre for Drug Research and Development's (CDRD, now adMare BioInnovations) Project Search and Evaluation Division (2007-2015) where he was responsible for establishing and managing partnerships with academic institutions and identifying projects with therapeutic and commercial potential.
Before CDRD, he held various positions at Inflazyme Pharmaceuticals Ltd. (2000-2007), a Vancouver-based biotechnology company specializing in the development of treatments for respiratory and inflammatory diseases. Prior to Inflazyme, John led the natural products group at Ocean Nutrition Canada (1999-2000) after having completed a postdoctoral fellowship in the Marine Natural Products Chemistry group at the National Research Council in Halifax, Nova Scotia (1998-1999).
John holds a BSc (Honours) from Bishop's University (1992) and a PhD from the University of British Columbia (1997). His PhD research on naturally-derived anticancer compounds produced the drug candidate HTI-286 that was licensed to Wyeth, where it progressed to Phase II clinical trials.
John commented "I am excited to join the excellent team that Matt and Jackie Stang founded and are building at DELIC to continue unlocking the potential of ketamine and psilocybin, and the potentially addition of other psychedelics, to address psychiatric, behavioral and mental health disorders plaguing our society. DELIC is positioning itself to be a leader in both the educational and scientific sides of the burgeoning psychedelic industry."
The Company's Board of Directors have approved the granting of 250,000 incentive stock options to Dr. Coleman at an exercise price of $0.55 as of the closing of business on March 9, 2021. The stock options are exercisable for a period of 3 years in accordance with the terms of the Company's Incentive Stock Option plan.
About DELIC DELIC Always Expanding. In All Ways.
DELIC was formed in 2019 to address the growing interest in psychedelic wellness backed by science. DELIC was the first psychedelic umbrella platform and is currently a trusted source for those interested in psychedelic culture, psychedelic clinics, and more. DELIC's offerings include, Ketamine Infusion Center (under binding acquisition agreement), a limited liability corporation formed under the laws of Arizona and runs two ketamine clinics in Arizona and California, "Reality Sandwich", a free public education platform providing psychedelic guides, news and culture, "Meet Delic", the first ever psychedelic wellness summit, and "The Delic", an e-commerce lifestyle brand. For more information, check out www.deliccorp.com.
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.
This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
Forward-Looking Information and Statements
This press release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of DELIC's control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or may contain statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "will continue", "will occur" or "will be achieved". The forward-looking information and forward-looking statements contained herein may include, but are not limited to, information concerning listing on the Canadian Securities Exchange, anticipated continued growth in the health and wellness sector (and, in particular, related to psychedelics), the continued emergence of psychedelics from stigmas, the ability of the Company to maintain sensible messaging, the ability of the Company to avoid dogmatic practices and binary rhetoric, the ability of DELIC to successfully achieve business objectives, and expectations for other economic, business, and/or competitive factors.
By identifying such information and statements in this manner, DELIC is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of DELIC to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, DELIC has made certain assumptions. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.
Although DELIC believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and DELIC does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to DELIC or persons acting on its behalf is expressly qualified in its entirety by this notice.